Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care

Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia

(2022) Anne Langsted et al.   Current Atherosclerosis Reports

Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic

(2022) Lotte M. de Boer et al.   ATHEROSCLEROSIS

Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?

(2022) Rodrigo Alonso et al.   Current Atherosclerosis Reports

Key Questions About Familial Hypercholesterolemia

(2022) Allan D. Sniderman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol

(2022) Calvin Yeang et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements

(2021) Calvin Yeang et al.   JOURNAL OF LIPID RESEARCH

Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a)

(2021) Don P. Wilson et al.   Current Opinion in Endocrinology Diabetes and Obesity

Genome-Wide Association Study and Identification of a Protective Missense Variant on Lipoprotein(a) Concentration

(2021) M. Abdullah Said et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

(2021) Glen J. Pearson et al.   CANADIAN JOURNAL OF CARDIOLOGY

The Residual Risk Odyssey

(2021) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

(2021) Antonio Gallo et al.   JACC-Cardiovascular Imaging

Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia

(2021) Martine Paquette et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

(2021) Gissette Reyes-Soffer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population

(2021) Wann Jia Loh et al.   ATHEROSCLEROSIS

Dyslipidemia and aortic valve disease

(2021) Pedro Mata et al.   CURRENT OPINION IN LIPIDOLOGY

Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study

(2021) Nina Strandkjær et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A resilient type of familial hypercholesterolaemia: case–control follow-up of genetically characterized older patients in the SAFEHEART cohort

(2021) Leopoldo Pérez de Isla et al.   European Journal of Preventive Cardiology

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

(2020) Vera A. Bittner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care

(2020) Gerald F. Watts et al.   Nature Reviews Cardiology

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

(2020) Sotirios Tsimikas et al.   NEW ENGLAND JOURNAL OF MEDICINE

The dedicated “Lp(a) clinic”: A concept whose time has arrived?

(2020) Sotirios Tsimikas et al.   ATHEROSCLEROSIS

Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?

(2020) Zanfina Ademi et al.   ATHEROSCLEROSIS

Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease

(2020) Pengwei Hu et al.   CIRCULATION

What Is Familial Hypercholesterolemia, and Why Does It Matter?

(2020) Amit V. Khera et al.   CIRCULATION

SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia

(2020) Antonio Gallo et al.   ATHEROSCLEROSIS

Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia

(2020) Mark Trinder et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a) and calcific aortic valve stenosis: A systematic review

(2020) Raviteja R. Guddeti et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease

(2020) Mark Trinder et al.   JAMA Cardiology

Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia

(2020) Leopoldo Pérez de Isla et al.   EUROPEAN HEART JOURNAL

Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia

(2020) Gerald F. Watts et al.   Heart Lung and Circulation

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among Seven Ethnic Groups

(2019) Guillaume Paré et al.   CIRCULATION

Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease

(2019) Michael B. Boffa et al.   Nature Reviews Cardiology

Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia

(2019) Katrina L. Ellis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Screening for High Lipoprotein(a)

(2019) George Thanassoulis   CIRCULATION

Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia

(2019) Sofía Perez-Calahorra et al.   ATHEROSCLEROSIS

Statin therapy increases lipoprotein(a) levels

(2019) Sotirios Tsimikas et al.   EUROPEAN HEART JOURNAL

Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group

(2019) Don P. Wilson et al.   Journal of Clinical Lipidology

Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification

(2019) Nicolas Perrot et al.   JAMA Cardiology

Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes

(2019) Claudia Lamina et al.   JAMA Cardiology

Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does it Make a Difference in the Clinic?

(2019) Dick C. Chan et al.   CLINICAL CHEMISTRY

Elevated Lipoprotein(a) and Risk of Ischemic Stroke

(2019) Anne Langsted et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention

(2019) Christian M. Madsen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia

(2019) Ye-Xuan Cao et al.   ATHEROSCLEROSIS

HEART UK consensus statement on Lipoprotein(a): A call to action

(2019) Jaimini Cegla et al.   ATHEROSCLEROSIS

Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities

(2019) A. Vuorio et al.   JOURNAL OF INTERNAL MEDICINE

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

(2018) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The complex molecular genetics of familial hypercholesterolaemia

(2018) Amanda J. Berberich et al.   Nature Reviews Cardiology

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

(2018) Stephen Burgess et al.   JAMA Cardiology

ClinVar database of global familial hypercholesterolemia-associated DNA variants

(2018) Michael A. Iacocca et al.   HUMAN MUTATION

A comprehensive map of single-base polymorphisms in the hypervariable LPA kringle IV type 2 copy number variation region

(2018) Stefan Coassin et al.   JOURNAL OF LIPID RESEARCH

Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a)

(2017) Alpo Vuorio et al.   EUROPEAN HEART JOURNAL

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK

(2017) Marion Kerr et al.   EUROPEAN HEART JOURNAL

Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing

(2017) Joshua W. Knowles et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia

(2017) Barbara Sjouke et al.   Journal of Clinical Lipidology

Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia

(2017) Pablo Lázaro et al.   Journal of Clinical Lipidology

Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis

(2017) Leo E Akioyamen et al.   BMJ Open

Putting Into Perspective the Hazards of Untreated Familial Hypercholesterolemia

(2017) Paul N. Hopkins   Journal of the American Heart Association

Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases

(2016) Florian Kronenberg   CARDIOVASCULAR DRUGS AND THERAPY

Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations

(2016) Hayato Tada et al.   CIRCULATION JOURNAL

Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis

(2016) Calvin Yeang et al.   CURRENT OPINION IN CARDIOLOGY

Lipoprotein apheresis to treat elevated lipoprotein (a)

(2016) Elisa Waldmann et al.   JOURNAL OF LIPID RESEARCH

Structure, function, and genetics of lipoprotein (a)

(2016) Konrad Schmidt et al.   JOURNAL OF LIPID RESEARCH

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

(2016) Amit V. Khera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Child–Parent Familial Hypercholesterolemia Screening in Primary Care

(2016) David S. Wald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study

(2016) Anne Langsted et al.   Lancet Diabetes & Endocrinology

Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population

(2016) Pia R. Kamstrup et al.   JACC-Heart Failure

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

(2015) Guy De Backer et al.   ATHEROSCLEROSIS

‘LDL-C’ = LDL-C + Lp(a)-C

(2015) Calvin Yeang et al.   CURRENT OPINION IN LIPIDOLOGY

The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification

(2015) Renato Fellin et al.   GENE

Prevalence and treatment of familial hypercholesterolaemia in Australian communities

(2015) Gerald F. Watts et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia

(2015) R. Vongpromek et al.   JOURNAL OF INTERNAL MEDICINE

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

(2015) Byambaa Enkhmaa et al.   JOURNAL OF LIPID RESEARCH

Increased Aortic Valve Calcification in Familial Hypercholesterolemia

(2015) Gert-Jan R. ten Kate et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Lipoprotein(a) Levels in Familial Hypercholesterolemia

(2014) Rodrigo Alonso et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

(2013) Josef Leebmann et al.   CIRCULATION

When should we measure lipoprotein (a)?

(2013) K. M. Kostner et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia

(2013) Zanfina Ademi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population

(2013) Pia R. Kamstrup et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Low-Density Lipoprotein Receptor Gene Familial Hypercholesterolemia Variant Database: Update and Pathological Assessment

(2012) Ebele Usifo et al.   ANNALS OF HUMAN GENETICS

Farnesoid X receptor represses hepatic human APOA gene expression

(2011) Indumathi Chennamsetty et al.   JOURNAL OF CLINICAL INVESTIGATION

Variation in LPA Is Associated with Lp(a) Levels in Three Populations from the Third National Health and Nutrition Examination Survey

(2011) Logan Dumitrescu et al.   PLoS One

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

The LDL Receptor

(2009) Joseph L. Goldstein et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

(2009) Beate R Jaeger et al.   Nature Reviews Cardiology

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population

(2007) Pia R. Kamstrup et al.   CIRCULATION